pSivida Corp


Medidur Technology

The continued advancement of drug delivery technology is critically important in the drive to both increase efficacy and improve patient safety. Furthermore, the use of novel drug delivery systems is an increasingly important strategy for pharmaceutical and biotechnology companies to enable the delivery of new drugs while also extending the commercial life of their current drugs.

pSivida's Medidur™ Technology is a miniaturized, injectable, sustained-release drug delivery system designed to advance the treatment of medical conditions in critical areas such as ophthalmology, oncology and cardiology.

The properties of our Medidur Technology make it an ideal platform for advancing the development of drug delivery:

Medidur is licensed for certain ophthalmic applications to Pfizer Inc. and Alimera Sciences has licensed Medidur drug delivery technology for our lead development product ILUVIEN™, (fluocinolone acetonide for the treatment of diabetic macular edema) and certain other ophthalmic products. Over 1,000 people have been enrolled in Medidur clinical trials to-date.

ILUVIEN is specifically designed to release fluocinolone acetonide for periods of up to 36 months. The implant is inserted with a 25 gauge needle into the back of the eye during an outpatient office visit, which enables self-sealing of the wound. This insertion procedure is very similar to an intravitreal injection, a procedure commonly employed by retinal specialists.

ILUVIEN has completed two Phase III clinical trials in diabetic macular edema and our partner Alimera Sciences filed the NDA with the FDA in May 2011. We anticipate a decision from the FDA by the end of 2011. In addition, Alimera is conducting Phase II clinical trials with Iluvien in wet and dry age-related macular degeneration (AMD) and retinal vein occlusion (RVO).